IgA Nephropathy Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, IgA Nephropathy pipeline constitutes 30+ key companies continuously working towards developing 30+ IgA Nephropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"IgA Nephropathy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the IgA Nephropathy Market.

The IgA Nephropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the IgA Nephropathy Pipeline Report: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel IgA Nephropathy treatment therapies with a considerable amount of success over the years.
• IgA Nephropathy companies working in the treatment market are Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Visterra, Chinook Therapeutics, Novartis, Travere Therapeutics, and others, are developing therapies for the IgA Nephropathy treatment
• Emerging IgA Nephropathy therapies in the different phases of clinical trials are- Research programme: IgA proteases, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, Sibeprenlimab, Atrasentan, LNP023, Sparsentan, HR19042, and others are expected to have a significant impact on the IgA Nephropathy market in the coming years.
• In June 2023, According to an agreement and merger plan signed by Chinook Therapeutics, Inc. and Novartis AG, Chinook will be purchased by Novartis for $40 per share in cash, or a total of $3.2 billion.
• On November 7, 2022, Positive findings from a Phase 2 clinical trial of IONIS-FB-LRx in patients with immunoglobulin A nephropathy (IgAN) were presented by Ionis Pharmaceuticals, Inc. The study's findings were displayed in a poster session during Kidney Week 2022 of the American Society of Nephrology (ASN).
• On November 05, 2022, Atacicept in immunoglobulin A nephropathy (IgAN) and MAU868 in kidney transplant, two of the company's product candidates, were the subjects of new clinical data presented, according to Vera Therapeutics, Inc. These findings were presented orally and in a poster at the American Society of Nephrology (ASN) Kidney Week 2022 Annual Meeting, which took place in Orlando, Florida, from November 3-6, 2022.
• In October 2022, The U.S. Food and Drug Administration (FDA) has granted IND clearance for TST004, a best-in-class, humanised monoclonal antibody that targets MASP2. This information was released by Transcenta Holding Limited. A crucial enzyme in the lectin pathway's beginning of complement activation is MASP2, or mannose-binding protein-associated serine protease 2. Numerous human disorders, including immunoglobulin A nephropathy (IgAN) and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA), have been linked to the activation of the lectin pathway, according to studies. Therefore, blocking MASP2 could be a possible therapeutic strategy for conditions caused by lectin pathway activation.
• In February 2021, "A Phase II, Open-Label, BasketStudy of Atrasentan in Patients With Proteinuric Glomerular Diseases" is the name of the experiment that Chinook Therapeutics, Inc. started. There will be about 100 participants recruited in the study.

IgA Nephropathy Overview
The most prevalent primary glomerular disease that can lead to end-stage renal failure (ESRD) is IgA nephropathy (IgAN), also known as Berger's disease. IgA nephropathy can be categorised as an autoimmune condition due to the crucial interaction between an intrinsic antigen (galactose-deficient IgA1) and circulating anti-glycan antibodies.

Get a Free Sample PDF Report to know more about IgA Nephropathy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging IgA Nephropathy Drugs Under Different Phases of Clinical Development Include:
• Research programme: IgA proteases Selecta Biosciences
• AP 305: Shanghai Alebund Pharmaceuticals
• ADR-001: Rohto Pharmaceutical
• MY 008: Wuhan Createrna Science and Technology
• SHR-2010: Guangdong Hengrui Pharmaceutical
• IONIS FB: LRx Ionis Pharmaceuticals
• HR19042: Jiangsu HengRui Medicine Co., Ltd.
• Sibeprenlimab: Visterra
• Atrasentan: Chinook Therapeutics
• LNP023: Novartis Pharmaceuticals
• Sparsentan: Travere Therapeutics
• LNP023: Novartis
• HR19042: Jiangsu HengRui Medicine Co., Ltd.

IgA Nephropathy Route of Administration
IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

IgA Nephropathy Molecule Type
IgA Nephropathy Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

IgA Nephropathy Pipeline Therapeutics Assessment
• IgA Nephropathy Assessment by Product Type
• IgA Nephropathy By Stage and Product Type
• IgA Nephropathy Assessment by Route of Administration
• IgA Nephropathy By Stage and Route of Administration
• IgA Nephropathy Assessment by Molecule Type
• IgA Nephropathy by Stage and Molecule Type

DelveInsight's IgA Nephropathy Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further IgA Nephropathy product details are provided in the report. Download the IgA Nephropathy pipeline report to learn more about the emerging IgA Nephropathy therapies at:
https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the IgA Nephropathy Therapeutics Market include:
Key companies developing therapies for IgA Nephropathy are - Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, and others.

IgA Nephropathy Pipeline Analysis:
The IgA Nephropathy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of IgA Nephropathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for IgA Nephropathy Treatment.
• IgA Nephropathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• IgA Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the IgA Nephropathy market.
• The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about IgA Nephropathy drugs and therapies-
https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

IgA Nephropathy Pipeline Market Drivers
• Increase in prevalence of IgA Nephropathy (IgAN), increment in the number of government initiatives to spread awareness are some of the important factors that are fueling the IgA Nephropathy Market.

IgA Nephropathy Pipeline Market Barriers
• However, lack of in-depth understanding of the disease pathogenesis, the unreported and undiagnosed IgA Nephropathy cases and other factors are creating obstacles in the IgA Nephropathy Market growth.

Scope of IgA Nephropathy Pipeline Drug Insight
• Coverage: Global
• Key IgA Nephropathy Companies: Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Visterra, Chinook Therapeutics, Novartis, Travere Therapeutics, and others
• Key IgA Nephropathy Therapies: Research programme: IgA proteases, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, Sibeprenlimab, Atrasentan, LNP023, Sparsentan, HR19042, and others
• IgA Nephropathy Therapeutic Assessment: IgA Nephropathy current marketed and IgA Nephropathy emerging therapies
• IgA Nephropathy Market Dynamics: IgA Nephropathy market drivers and IgA Nephropathy market barriers

Request for Sample PDF Report for IgA Nephropathy Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. IgA Nephropathy Report Introduction
2. IgA Nephropathy Executive Summary
3. IgA Nephropathy Overview
4. IgA Nephropathy- Analytical Perspective In-depth Commercial Assessment
5. IgA Nephropathy Pipeline Therapeutics
6. IgA Nephropathy Late Stage Products (Phase II/III)
7. IgA Nephropathy Mid Stage Products (Phase II)
8. IgA Nephropathy Early Stage Products (Phase I)
9. IgA Nephropathy Preclinical Stage Products
10. IgA Nephropathy Therapeutics Assessment
11. IgA Nephropathy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. IgA Nephropathy Key Companies
14. IgA Nephropathy Key Products
15. IgA Nephropathy Unmet Needs
16 . IgA Nephropathy Market Drivers and Barriers
17. IgA Nephropathy Future Perspectives and Conclusion
18. IgA Nephropathy Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

IgA Nephropathy Market https://www.delveinsight.com/report-store/iga-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'IgA Nephropathy-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

IgA Nephropathy Epidemiology https://www.delveinsight.com/report-store/iga-nephropathy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'IgA Nephropathy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.